40 related articles for article (PubMed ID: 35996877)
21. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
22. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
Freise KJ; Hu B; Salem AH
Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
[TBL] [Abstract][Full Text] [Related]
23. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
24. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug-drug interaction predictions using a PBPK approach.
Bhatnagar S; Mukherjee D; Salem AH; Miles D; Menon RM; Gibbs JP
Cancer Chemother Pharmacol; 2021 Apr; 87(4):465-474. PubMed ID: 33398386
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
[TBL] [Abstract][Full Text] [Related]
26. Considering the Oral Bioavailability of Protein Kinase Inhibitors: Essential in Assessing the Extent of Drug-Drug Interaction and Improving Clinical Practice.
Le Louedec F; Puisset F; Chatelut E; Tod M
Clin Pharmacokinet; 2023 Jan; 62(1):55-66. PubMed ID: 36631685
[TBL] [Abstract][Full Text] [Related]
27. Application of physiologically based pharmacokinetics modeling in the research of small-molecule targeted anti-cancer drugs.
Wang X; Chen F; Guo N; Gu Z; Lin H; Xiang X; Shi Y; Han B
Cancer Chemother Pharmacol; 2023 Oct; 92(4):253-270. PubMed ID: 37466731
[TBL] [Abstract][Full Text] [Related]
28. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
Rowland Yeo K; Gil Bergland E; Chen Y
Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38686708
[TBL] [Abstract][Full Text] [Related]
29. Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK-Informed Analysis.
Mukherjee D; Brackman DJ; Suleiman AA; Zha J; Menon RM; Salem AH
J Clin Pharmacol; 2023 Jan; 63(1):119-125. PubMed ID: 35996877
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax: A First-in-Class Oral BCL-2 Inhibitor for the Management of Lymphoid Malignancies.
King AC; Peterson TJ; Horvat TZ; Rodriguez M; Tang LA
Ann Pharmacother; 2017 May; 51(5):410-416. PubMed ID: 28056525
[TBL] [Abstract][Full Text] [Related]
31. Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Megías-Vericat JE; Solana-Altabella A; Ballesta-López O; Martínez-Cuadrón D; Montesinos P
Ann Hematol; 2020 Sep; 99(9):1989-2007. PubMed ID: 32683457
[TBL] [Abstract][Full Text] [Related]
32. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Waldron M; Winter A; Hill BT
Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
[TBL] [Abstract][Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]